Octagon Capital Advisors LP
13F Reported Value
ⓘ$903.6M
Holdings
29
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Octagon Capital Advisors LP disclosed 29 positions worth $903.6M in its Form 13F-HR for Q1 2026, led by $DNTH (Dianthus Therapeutics, Inc. /DE/) at 18.1% of the equity portfolio, followed by $COGT and $ABVX. During the quarter the fund opened 8 new positions and exited 6 — including a new stake in $DFTX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Octagon Capital Advisors LP’s Form 13F-HR filing with the SEC under CIK 1839435.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 26.8#2,490
Quality
$163.4M1,946,667 sh - —
Quality
$90.5M2,350,000 sh - —
Quality
$75.4M677,000 sh - 9.2
Quality
$62.4M2,830,700 sh - —
Quality
$46.1M2,440,000 sh - —
Quality
$45.5M1,971,054 sh - 4.1
Quality
$39.6M8,859,911 sh - 29.2
Quality
$35.4M425,000 sh - 32.7
Quality
$31.3M338,900 sh - 28.6
Quality
$30.6M1,748,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Dianthus Therapeutics, Inc. /DE/$DNTH | 26.8#2,490 | $163.4M | 1,946,667 |
 Cogent Biosciences, Inc.$COGT | — | $90.5M | 2,350,000 |
 Abivax S.A.$ABVX | — | $75.4M | 677,000 |
 ALUMIS INC.$ALMS | 9.2 | $62.4M | 2,830,700 |
 Definium Therapeutics, Inc.$DFTX | — | $46.1M | 2,440,000 |
 ArriVent BioPharma, Inc.$AVBP | — | $45.5M | 1,971,054 |
 Taysha Gene Therapies, Inc.$TSHA | 4.1 | $39.6M | 8,859,911 |
 Kymera Therapeutics, Inc.$KYMR | 29.2 | $35.4M | 425,000 |
 Mirum Pharmaceuticals, Inc.$MIRM | 32.7 | $31.3M | 338,900 |
 BioAge Labs, Inc.$BIOA | 28.6 | $30.6M | 1,748,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Octagon Capital Advisors LP's 29 positions.
Showing top 10 of 29 holdings.
Sector Allocation
Healthcare
$903.6M
Full Holdings — Octagon Capital Advisors LP (Q1 2026)
All 29 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $DNTH | Dianthus Therapeutics, Inc. /DE/ | $163.4M | 18.1% | -19% | 26.8 |
| 2 | $COGT | Cogent Biosciences, Inc. | $90.5M | 10.0% | +0% | — |
| 3 | $ABVX | Abivax S.A. | $75.4M | 8.3% | -10% | — |
| 4 | $ALMS | ALUMIS INC. | $62.4M | 6.9% | +12% | 9.2 |
| 5 | $DFTX | Definium Therapeutics, Inc. | $46.1M | 5.1% | NEW | — |
| 6 | $AVBP | ArriVent BioPharma, Inc. | $45.5M | 5.0% | +0% | — |
| 7 | $TSHA | Taysha Gene Therapies, Inc. | $39.6M | 4.4% | +0% | 4.1 |
| 8 | $KYMR | Kymera Therapeutics, Inc. | $35.4M | 3.9% | -21% | 29.2 |
| 9 | $MIRM | Mirum Pharmaceuticals, Inc. | $31.3M | 3.5% | NEW | 32.7 |
| 10 | $BIOA | BioAge Labs, Inc. | $30.6M | 3.4% | +9% | 28.6 |
| 11 |  $CNTA | Centessa Pharmaceuticals plc | $29.8M | 3.3% | +0% | — |
| 12 |  $KALV | KalVista Pharmaceuticals, Inc. | $29.2M | 3.2% | +14% | 25.9 |
| 13 |  $XENE | Xenon Pharmaceuticals Inc. | $28.5M | 3.1% | NEW | 12.9 |
| 14 |  $TERN | Terns Pharmaceuticals, Inc. | $27.9M | 3.1% | NEW | — |
| 15 |  $OCUL | OCULAR THERAPEUTIX, INC | $26.8M | 3.0% | +21% | 12.8 |
| 16 |  $PALI | PALISADE BIO, INC. | $18.0M | 2.0% | +7% | — |
| 17 |  $TRVI | Trevi Therapeutics, Inc. | $17.7M | 2.0% | -47% | — |
| 18 |  $IRON | Disc Medicine, Inc. | $17.3M | 1.9% | NEW | — |
| 19 |  $AKTS | Aktis Oncology, Inc. | $17.2M | 1.9% | NEW | — |
| 20 |  $CNTX | Context Therapeutics Inc. | $13.8M | 1.5% | NEW | — |
| 21 |  $DTIL | PRECISION BIOSCIENCES INC | $12.3M | 1.4% | +17% | 3.9 |
| 22 |  $DBVT | DBV Technologies S.A. | $12.0M | 1.3% | +0% | 6.1 |
| 23 |  $UNCY | Unicycive Therapeutics, Inc. | $6.6M | 0.7% | +0% | — |
| 24 |  $BBOT | BridgeBio Oncology Therapeutics, Inc. | $6.4M | 0.7% | -31% | — |
| 25 |  $LXEO | Lexeo Therapeutics, Inc. | $6.3M | 0.7% | -36% | — |
| 26 |  $PHVS | Pharvaris N.V. | $4.7M | 0.5% | -75% | — |
| 27 |  $CATX | Perspective Therapeutics, Inc. | $3.3M | 0.4% | NEW | — |
| 28 |  $EVMN | Evommune, Inc. | $3.3M | 0.4% | -71% | — |
| 29 |  $GOSS | Gossamer Bio, Inc. | $2.5M | 0.3% | -44% | 27.1 |
New Positions (8)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Octagon Capital Advisors LP including:
Track Octagon Capital Advisors LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Octagon Capital Advisors LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Octagon Capital Advisors LP
13F Pro is an AI hedge fund tracker and stock research platform. For Octagon Capital Advisors LP (SEC CIK: 1839435), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Octagon Capital Advisors LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.